Effects of AQA39 on contractile performance of isolated mammalian ventricular myocardium.
AQA39 is a new cardioactive agent with, at low dosages, a minute positive inotropic action on ventricular myocardial tissue probably mediated through the calcium sequestering membraneous systems. At higher concentrations AQA39 depressed myocardial performance probably due to inhibition of the slow calcium channels.
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002415:Cats; D066298:In Vitro Techniques; D054833:Isoindoles; D009186:Myelin Sheath / Q000502:physiology; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000166:cytology; D010210:Papillary Muscles / Q000187:drug effects; D010797:Phthalimides / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D054833:Isoindoles; D010797:Phthalimides; C030532:falipamil